Great Management - Grant Saves Shareholder Dilution Again!! The recent PONTIAC trial grant saves shareholders 1,268,000 shares in dilution. Since 2018 the company has only performed 4 financings, all Non Brokered with No Warrants.
-
July 29, 2024 (Unknown) - $1.50 per common share for net proceeds of $600,000 CAD
-
Dec 23, 2020 (One Placee) - $1.50 per common share for net proceeds of $645,000 CAD
-
June 30, 2020 (Two Placees) - $1.50 per common share for net proceeds of $1,350,000 CAD
-
Feb 2, 2018 (One Placee) - $ .50 per common share for net proceeds of $1,250,000 CAD
-
Arch Shareholders have raised $3,845,000 from the markets while $12,750,000 in grant funding from the Canadian Government. This recent PONTIAC trial grant adds an additional $1,900,000 progressing Cilastatin in a Phase II clinical trial.